AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

14.640

+1.0007.33%

Volume:3.49M

Turnover:50.35M

Market Cap:4.96B

PE:-490.99

High:14.790

Open:14.550

Low:14.010

Close:13.640

52wk High:29.640

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.38

T/O Rate:1.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.030

ROE:-1.85%

ROA:1.15%

PB:8.45

PE(LYR):-491.00

Loading ...

Overview Company News Filings

Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?

Simply Wall St.

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones

Simply Wall St.

ASX Stocks That May Be Trading Below Their Estimated Value In January 2026

Simply Wall St.

How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Simply Wall St.

ASX Growth Companies With High Insider Ownership In January 2026

Simply Wall St.

Stock Track | Telix Pharmaceuticals Plummets 5.05% as Q4 Results Fail to Excite Investors

BUZZ-Australia's Telix Pharmaceuticals down as Citi sees no surprise in Q4 results

Telix Achieves FY 2025 Guidance With US$804M (a$1.2B) Revenue, Accelerates Growth With Gozellix Launch

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Achieves FY 2025 Unaudited Revenue of US$804 Mln

THOMSON REUTERS

BRIEF-Telix Pharmaceuticals Posts FY Unaudited Group Revenue Of $804 Million

Telix Pharmaceuticals Ltd - FY Unaudited Group Revenue of US$804 Mln

THOMSON REUTERS

BUZZ-Australia's Telix Pharmaceuticals rises on China acceptance of new drug application

Telix Says Chinese Regulator Accepts New Drug Application Filing for Prostate Cancer Imaging Agent Preparation Kit; Shares Up 5%

MT Newswires Live

Stock Track | TELIX PHARMACEUTICALS LTD Soars 5.01% as Chinese NMPA Accepts New Drug Application for Prostate Cancer Imaging

Telix Pharmaceuticals Shares Fall Nearly 1% After Dosing First US Patient in Phase Three Prostate Cancer Diagnosis Imaging Study

MT Newswires Live

Telix Pharmaceuticals Doses First U.S. Patient in Phase 3 BiPASS Prostate Cancer Diagnosis Study

How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Expanding Radiopharma Platform And Streamlining Incentives

Simply Wall St.

DIARY-Australia, New Zealand corporate earnings week ahead

Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":14.64,"timestamp":1775801520000,"preClose":13.64,"halted":0,"volume":3493084,"delay":0,"changeRate":0.07331378299120234,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.029817126335588223,"marketStatus":"Market Closed","change":1,"latestTime":"04-10 16:12:00 AEST","open":14.55,"high":14.79,"low":14.01,"amount":50351824,"amplitude":0.057185,"askPrice":14.65,"askSize":5000,"bidPrice":14.55,"bidSize":168,"shortable":3,"etf":0,"ttmEps":-0.029817126335588223,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1776038400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":13.64,"openAndCloseTimeList":[[1775779200000,1775800800000]],"volumeRatio":1.3836915765610471,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":13.64,"auctionPrice":14.64,"auctionVolume":368721,"auction":3,"marketStatus":"盘后竞价","timestamp":1775801407939}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"1.15%","roe":"-1.85%","lyrEps":-0.029817,"volumeRatio":1.3836915765610471,"shares":338721355,"dividePrice":0,"high":14.79,"amplitude":0.057185,"preClose":13.64,"low":14.01,"week52Low":8.26,"pbRate":"8.45","psRate":"4.37","week52High":29.64,"institutionHeld":0,"latestPrice":14.64,"committee":-0.934985,"eps":-0.029817126335588223,"divideRate":0,"volume":3493084,"delay":0,"ttmEps":-0.029817126335588223,"open":14.55,"prevYearClose":11.2,"prevWeekClose":12.95,"prevMonthClose":13.66,"prevQuarterClose":13.66,"fiveDayClose":13.2,"twentyDayClose":10.76,"sixtyDayClose":11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608131070","title":"Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2608131070","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608131070?lang=en_us&edition=fundamental","pubTime":"2026-01-31 23:41","pubTimestamp":1769874099,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals reported that China’s NMPA has accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px (Illuccix®), supported by a pivotal Phase 3 study in Chinese patients with biochemical recurrence.\nIn parallel, the first patient has now been dosed in a Phase 3 registration study in Japan, highlighting Telix’s push to expand TLX591-Px across major Asian nuclear medicine markets in prostate cancer care.\nWe’ll next examine how this progress toward broader...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-asian-tlx591-px-expansion-progress-change-the-bull-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-asian-tlx591-px-expansion-progress-change-the-bull-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK7067","TLX","PRGS","BK4139","TLX.AU","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607722363","title":"First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2607722363","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607722363?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:43","pubTimestamp":1769643780,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px  for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital  in Kamakura, Japan.Illuccix Japan[1] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of 68Ga-PSMA-11 PET/CT[2] in Japanese patients with biochemically recurrent  prostate cancer following prior radical prostatectomy. The study will enroll up to 105 Japanese men at 11 sites and data are intended to support a future marketing authorization application for TLX591-Px in Japan.The primary objective of the study is to compare the sensitivity of 68Ga-PSMA-11 PET/CT to conventional imaging  for the detection of metastatic lesions. Secondary objectives include evaluating diagnostic performance for local and distant lesions, safety and to","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/first-patient-dosed-in-pivotal-phase-3-study-of-tlx591-px-illuccix-for-prostate-cancer-imaging-in-japanese-patients-302673282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCR","BK4141","ASX","BK4139","ASX.AU","BK7067","BK7039","TLX.AU","SEC.AU","BK4543","BK4526","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606614203","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606614203","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606614203?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:33","pubTimestamp":1769470391,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after Chinese regulators accepted a New Drug Application for its Illuccix prostate cancer imaging agent, and the company reported first patient dosing in a US Phase 3 diagnostic trial.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the regulatory momentum in China and the US, Telix’s share price return over the past 90 days shows a 34.31% decline, contributing to a 60.23% drop in 1-year total shareholder return. However, the 5-year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-key-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-key-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX.AU","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606269605","title":"ASX Stocks That May Be Trading Below Their Estimated Value In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606269605","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606269605?lang=en_us&edition=fundamental","pubTime":"2026-01-26 03:04","pubTimestamp":1769367894,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of uncertainty marked by mixed unemployment figures and global economic tensions, investors are keenly observing opportunities that may arise from these fluctuations. In such an environment, identifying stocks that could be trading below their estimated value can be particularly appealing, as they offer potential for growth when market conditions stabilize.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-stocks-that-may-be-trading-below-their-estimated-value-i-6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-stocks-that-may-be-trading-below-their-estimated-value-i-6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","BK7044","BK7051","KGN.AU","BK7122","SPZ.AU","BK7133","BK7060","BK7115","SRV.AU","XKO.AU","DRO.AU","360.AU","BK7154","BK7504","BK7078","LGI.AU","BK7153","JHX.AU","BK7084","BET.AU","BK7506","CMW.AU","GLN.AU","BK7104","BK7067","BK7164","BK7095","ABV.AU","BK7049","XAO.AU","BK7047","RMS.AU","XJO.AU","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605595236","title":"How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2605595236","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605595236?lang=en_us&edition=fundamental","pubTime":"2026-01-24 14:32","pubTimestamp":1769236341,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently reported that China’s NMPA accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px, while the first U.S. patient was dosed in the BiPASS Phase 3 trial assessing Illuccix and Gozellix in pre-biopsy diagnosis.\nEarly data showing high positive predictive value in Chinese patients and a trial aimed at reducing unnecessary biopsies highlight how Telix’s PSMA-PET portfolio could influence prostate cancer care pathways across major...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-china-nmpa-nda-acceptance-and-us-bipass-milestone-at-tel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-china-nmpa-nda-acceptance-and-us-bipass-milestone-at-tel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","BK4139","BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605414594","title":"ASX Growth Companies With High Insider Ownership In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414594","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605414594?lang=en_us&edition=fundamental","pubTime":"2026-01-23 03:09","pubTimestamp":1769108984,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a boost from Wall Street's positive momentum and ongoing discussions around international trade, investors are keenly observing the implications of these global developments on local indices. In this context, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business in navigating such complex economic landscapes.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pol/polymetals-resources-shares/news/asx-growth-companies-with-high-insider-ownership-in-january-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pol/polymetals-resources-shares/news/asx-growth-companies-with-high-insider-ownership-in-january-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","TTT.AU","BK7036","TLX","BK7093","EIQ.AU","EMR.AU","BK7116","AV1.AU","POL.AU","3DP.AU","NWF.AU","PWH.AU","SEA.AU","BK7067","LM8.AU","TLX.AU","BK7016","BK7117","BK7506","BK4139","BK7095","WZR.AU","BK7051"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137397928","title":"Stock Track | Telix Pharmaceuticals Plummets 5.05% as Q4 Results Fail to Excite Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=1137397928","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137397928?lang=en_us&edition=fundamental","pubTime":"2026-01-21 07:58","pubTimestamp":1768953499,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (TLX.AU) saw its shares plummet 5.05% during intraday trading on Wednesday, marking one of its sharpest declines in recent weeks.The drop followed the company's Q4 2025...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605140624","title":"BUZZ-Australia's Telix Pharmaceuticals down as Citi sees no surprise in Q4 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605140624?lang=en_us&edition=fundamental","pubTime":"2026-01-21 07:56","pubTimestamp":1768953364,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals down as Citi sees no surprise in Q4 resultsUpdates** Shares of Australia's Telix Pharmaceuticals TLX.AX fall as much as 5.1% to A$10.9, their lowest level since Jan. 8** Stock logs its biggest intraday pct loss since Dec. 17** Citi says TLX's fourth-quarter results did not provide any major numerical surprises** TLX, after market hours on Tuesday, reported revenue of $208 million, up 46% year-on-year** Citi says revenue in line with Visible Alpha and its estimates** Brokerage says investors would likely shrug off results and instead focus on short-term milestone events for co's products** Earlier this week, TLX said China's NMPA accepted its New Drug Application for prostate imaging cancer product** Citi analysts, however, do not see the news as a major driver for stock** Citi keeps \"buy/high risk\" rating for TLX, target price of A$34 apiece** All 13 analysts covering the stock rate it \"buy\" or higher; their median PT is A$24.75 – LSEG data** Stoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4N3YL28S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989763005.USD","LU1064131342.USD","SG9999018857.SGD","LU0342679015.USD","LU1989764748.USD","LU2764262908.HKD","SG9999014906.USD","LU2271345857.HKD","BK7067","LU2264538146.SGD","LU1496350502.SGD","LU0158827948.USD","SG9999017495.SGD","LU2265009873.SGD","SG9999018865.SGD","LU2089284900.SGD","LU1804176565.USD","LU2095319765.USD","BK4534","BK4585","LU1989764664.SGD","LU2210149790.SGD","LU2210150020.SGD","SG9999014914.USD","LU0345774391.USD","GB00BDT5M118.USD","BK4112","LU0154236417.USD","SG9999014898.SGD","LU0971096721.USD","LU1633808545.USD","LU2028103732.USD","LU2720916845.USD","LU0158827781.USD","LU0345774631.USD","BK4597","BK4588","LU1989772923.USD","TLX.AU","LU2089283258.USD","LU0985320562.USD","SGXZ31699556.SGD","BK4581","SG9999014880.SGD","SPGI","BK4548","LU0097036916.USD","IE00B19Z9505.USD","LU0868494617.USD","LU0289960550.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604190368","title":"Telix Achieves FY 2025 Guidance With US$804M (a$1.2B) Revenue, Accelerates Growth With Gozellix Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190368?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA4P619M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604190333","title":"Telix Pharmaceuticals Ltd - Achieves FY 2025 Unaudited  Revenue of US$804 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190333","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190333?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA4P619M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604191643","title":"BRIEF-Telix Pharmaceuticals Posts FY Unaudited Group Revenue Of $804 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2604191643","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604191643?lang=en_us&edition=fundamental","pubTime":"2026-01-20 18:23","pubTimestamp":1768904599,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Posts FY Unaudited Group Revenue Of $804 MillionJan 20 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:FY UNAUDITED GROUP REVENUE OF US$804 MILLIONFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YK07X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604161573","title":"Telix Pharmaceuticals Ltd - FY Unaudited Group Revenue of US$804 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604161573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604161573?lang=en_us&edition=fundamental","pubTime":"2026-01-20 14:08","pubTimestamp":1768889298,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YK07X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604800154","title":"BUZZ-Australia's Telix Pharmaceuticals rises on China acceptance of new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2604800154","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604800154?lang=en_us&edition=fundamental","pubTime":"2026-01-20 08:39","pubTimestamp":1768869566,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals riseson China acceptance of new drug application ** Shares of Australia's Telix Pharmaceuticals TLX.AX rise as much as 6.3% to A$11.99, posting their biggest intraday pct gain in nearly two months** Stock touches its highest level since December-end** Biopharma co says the Chinese National Medical Products Administration  has accepted New Drug Application  for its prostate cancer diagnosis agent, Illuccix** Says NDA submitted in association with partner Grand Pharmaceutical Group 0512.HK in Greater China region ** Illuccix used as a scanning agent to detect prostate cancer in body** TLX among top gainers on the broader Australian benchmark index .AXJO, which is down 0.5%** TLX up 4.6% YTD after a 54.5% drop in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL6N3YL011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK4157","TNLX","TLX.AU","BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604015931","title":"Telix Says Chinese Regulator Accepts New Drug Application Filing for Prostate Cancer Imaging Agent Preparation Kit; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604015931","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604015931?lang=en_us&edition=fundamental","pubTime":"2026-01-20 07:30","pubTimestamp":1768865404,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the Chinese National Medical Products Administration Center for Drug Evaluation accepted the filing of a new drug application for TLX591-Px, or Illuccix, a kit for the preparation of gallium-68-PSMA-11, a prostate cancer imaging agent, according to a Tuesday Australian bourse filing.The application is supported by the results from the company's phase 3 registration study in China, the filing said. The study met its primary endpoint, with a nearly 95% overall patient-level positive predictive value for tumor detection with TLX591-Px.The application was submitted with Grand Pharmaceutical Group, the company's strategic partner for the Greater China region, per the filing.Telix Pharmaceuticals' shares jumped almost 5% in recent Tuesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129506613","title":"Stock Track | TELIX PHARMACEUTICALS LTD Soars 5.01% as Chinese NMPA Accepts New Drug Application for Prostate Cancer Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=1129506613","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129506613?lang=en_us&edition=fundamental","pubTime":"2026-01-20 07:20","pubTimestamp":1768864817,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price surge by 5.01% during the intraday trading session. This significant upward movement reflects strong investor confidence in the company's growth...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604390987","title":"Telix Pharmaceuticals Shares Fall Nearly 1% After Dosing First US Patient in Phase Three Prostate Cancer Diagnosis Imaging Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2604390987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604390987?lang=en_us&edition=fundamental","pubTime":"2026-01-19 10:25","pubTimestamp":1768789529,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals'  shares fell nearly 1% in recent trading on Monday after the firm said on Saturday that the first patient in the US was dosed in the Biopsy of the Prostate Avoidance Stratification Study  phase three trial to evaluate the use of the firm's prostate-specific membrane antigen positron emission tomography  imaging agents in the initial prostate cancer diagnosis setting.The agents include Illuccix and Gozellix, kits for the preparation of gallium-68 gozetotide injection.The study is designed to gain marketing authorization for gallium-68-PSMA-PET imaging in the pre-biopsy setting, and it will enroll 250 patients across sites in the US and Australia. It will study whether combining magnetic resonance imaging with imaging agents can improve diagnostic accuracy.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604153915","title":"Telix Pharmaceuticals Doses First U.S. Patient in Phase 3 BiPASS Prostate Cancer Diagnosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2604153915","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604153915?lang=en_us&edition=fundamental","pubTime":"2026-01-17 03:20","pubTimestamp":1768591212,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. has announced the dosing of the first U.S. patient in the BiPASS  Phase 3 trial. The study is evaluating the use of Telix's commercial PSMA-PET imaging agents, Illuccix and Gozellix, for initial prostate cancer diagnosis. Conducted at Urology Austin under the supervision of Dr. Brian Mazzarella, the BiPASS trial aims to enroll 250 patients across the U.S. and Australia. The primary objective is to determine whether combining MRI with 68Ga-PSMA-11 PET imaging can improve diagnostic accuracy and reduce unnecessary biopsies compared to current practices. Results from the study have not yet been presented; the trial is currently ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL7W75M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4588","SG9999014021.USD","SG9999014005.SGD","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","LU0314104364.USD","TLX.AU","LU2210150020.SGD","SG9999014039.USD","BK4112","BK4585","IE00B3QW5Z07.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603069950","title":"How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Expanding Radiopharma Platform And Streamlining Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2603069950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603069950?lang=en_us&edition=fundamental","pubTime":"2026-01-16 13:28","pubTimestamp":1768541291,"startTime":"0","endTime":"0","summary":"Recent news shows Telix Pharmaceuticals continuing to build out its radiopharmaceutical franchise, with Illuccix now commercially available in 17 countries and preparations under way to launch Gozellix, supported by expanded manufacturing and distribution capacity via the RLS Pharma acquisition.\nAn underappreciated development is the lapse of several conditional share and appreciation rights, which reduces potential future dilution and simplifies Telix’s capital structure, refining how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-may-respond-to-telix-pharmaceuticals-asxtlx-ex","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-may-respond-to-telix-pharmaceuticals-asxtlx-ex","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK7067","TLX","TLX.AU","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603937666","title":"DIARY-Australia, New Zealand corporate earnings week ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937666?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"DIARY-Australia, New Zealand corporate earnings week aheadJan 16  - Diary of Australia and New Zealand  corporate earnings for the week ahead AUSTRALIA & NEW ZEALAND EARNINGS Start DateStart Time RICCompany NameEvent Name20-Jan-2026NTSTLX.AXTelix Pharmaceuticals LtdFull Year 2025 Telix Pharmaceuticals Ltd Earnings Release** All times are listed in AMC - 'After market close', or BMO - 'Before market opens', or DBH - 'During business hours', or NTS - 'No time scheduled'** This Diary does not provide the EPS estimate figures. EPS figures can be retrieved from Workspace.Steps in Workspace to retrieve the EPS estimate:-Workspace Indicator-> Equities Guide-> Top Indices-> S&P/ASX 200-> Events-> Select Event types-> Select the company-> Estimates  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nL4N3YG1KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603656186","title":"Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603656186","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603656186?lang=en_us&edition=fundamental","pubTime":"2026-01-14 07:21","pubTimestamp":1768346478,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has reaffirmed its fiscal year 2026 guidance, with the company having two \"imminent\" drug launches due in the US within the year, according to a Tuesday Jefferies note.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":189,"code":"91000000","status":"200"}]}}